moderna mrna - Search News

Moderna Says FDA Will Consider Its New Flu Shot

FDA reverses course and will review Moderna’s mRNA flu shot, company says

The US Food and Drug Administration has reversed course and will review a new mRNA flu vaccine from Moderna, the pharmaceutical company said Wednesday,

· 19h

FDA to review Moderna's mRNA flu vaccine after initial rejection

BioSpace · 21h

FDA Reverses Course on Moderna’s mRNA Flu Shot Application, Promising August Decision

· 22h

FDA reverses course, will review Moderna's mRNA flu vaccine

Moderna said on Wednesday the U.S. Food and Drug Administration has agreed to review its influenza vaccine, reversing an earlier decision to reject the application, after the company made modification...

· 22h

FDA Reverses Course and Will Now Review Moderna’s Flu Shot

· 22h

F.D.A. Reverses Decision and Agrees to Review Moderna’s Flu Vaccine

BioSpace

Court Rejects Two Moderna Defenses in mRNA Vaccine Patent Row With Arbutus

Arbutus alleges that Moderna’s COVID-19 vaccine infringes on patents protecting its lipid nanoparticle delivery technology.

Moderna to Present at Upcoming Conferences in March 2026

Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences:

Just The News

Moderna threatens American jobs after FDA snubs mRNA flu shot, trial looked 'scientifically lax'

Drug observers puzzled by vaccine maker, which made a killing on COVID-19, failing to read the room with new administration. Moderna puts heat on FDA vaccines chief who's already been rebuked once by White House.

Moderna to Enter into Long-Term Strategic Agreement with the Government of Mexico

Signed Memorandum of Understanding supports "Plan Mexico," Mexico's strategic initiative to build a local mRNA

Blockonomi

Moderna (MRNA) Stock Slips Despite Beating Q4 Revenue and Earnings Estimates

Moderna (MRNA) stock fell 0.3% Friday despite beating Q4 revenue estimates at $678M and posting narrower loss of $2.11/share after FDA rejected flu vaccine review.